Clinical trial · no report yet · Phase 1/Phase 2
SOLARA
A Study of BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations
- NCT06706076 ↗
- Recruiting
- BlossomHill Therapeutics
- 9 commentary sources found
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built.
| Channel | Found | |
|---|---|---|
| X threads | 9 |
The trial
ClinicalTrials.gov- Official title
- A Phase 1/2 Open-Label, Multicenter, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of BH-30643 in Adult Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations (SOLARA)
- Phase
- Phase 1/Phase 2
- Status
- Recruiting
- Conditions
- NSCLC (Advanced Non-small Cell Lung Cancer)
- Interventions
- BH-30643; BH-30643 combo therapy with Carboplatin/Pemetrexed; BH-30643
- Arms
- Phase 1 Monotherapy Dose Escalation and Expansion · Experimental
- Phase 1 Combination Dose Escalation and Expansion · Experimental
- Phase 2 · Experimental
- Enrollment
- 675 (estimated)
- Primary outcomes
- Dose-limiting toxicities (DLTs) (Phase 1, Dose Escalation)
- Recommended Phase 2 dose (RP2D) (Phase 1, Dose Expansion/Optimization)
- Objective Response Rate (ORR) (Phase 2)
- Sponsor
- BlossomHill Therapeutics
- Start
- Jan 9, 2025
- Primary completion
- Jan 31, 2029 (estimated)
- Results posted
- No
- Registry record
- NCT06706076 · updated Aug 5, 2026